Argireline vs SNAP-8
A side-by-side research comparison of Argireline and SNAP-8 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Argireline | SNAP-8 |
|---|---|---|
| Full name | Argireline (Acetyl Hexapeptide-3) | SNAP-8 (Acetyl Octapeptide-3) |
| Category | Skin & Anti-Aging | Skin & Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Competes with SNAP-25 for position in SNARE complex, partially inhibiting vesicle docking and neurotransmitter release, reducing muscle contraction intensity. | More effectively competes with SNAP-25 for SNARE complex incorporation due to longer sequence, providing greater vesicle-membrane fusion inhibition. |
| Molecular weight | 889 Da | 1,075 Da |
| Half-life | 8-12 hours (topical) | 8-14 hours (topical) |
| Bioavailability | Moderate (topical) | Moderate (topical) |
| Typical dose | 5-10% solution | 3-10% solution |
| Frequency | 2x daily | 2x daily |
| Route | Topical | Topical |
Argireline reported benefits
- Reduces expression wrinkles up to 30%
- Non-invasive Botox alternative
- Prevents new wrinkle formation
- No muscle paralysis
- Stackable with other peptides
SNAP-8 reported benefits
- Superior to argireline
- Deeper wrinkle reduction
- Prevents expression lines
- Good skin penetration
Related comparisons
Research and educational reference only. Not medical advice.